The Carlat Psychiatry Podcast
Viibryd Goes Generic
Apr 1, 2024
Psychiatrist Chris Aiken, MD, and Psychiatric Nurse Practitioner Kellie Newsome discuss the generic form of Vilazodone, exploring its efficacy in managing depression and anxiety disorders, its impact on treating anxious depression, and its tolerability compared to SSRIs. They highlight the importance of understanding the drug's mechanism of action, onset of action, and remission rates from trials and studies.
12:47
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Velazodone's efficacy is average with low remission rates, questioning its uniqueness in the market.
- FDA approval lacks for Velazodone in anxiety disorders, showing limited efficacy and concerns over sexual side effects.
Deep dives
Effectiveness Comparison with Other Antidepressants
Velazidone's clinical trials do not suggest greater potency than other antidepressants and its efficacy is similar to modern-day antidepressants. Studies show its response rates are average, not exceptional. Remission rates on Velazidone are low, with only about 10% of patients achieving full remission, similar to a placebo. The drug's lack of efficacy in treatment-resistant depression and poor long-term data further question its unique selling proposition in the market.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
